reason report
bottom line reiter op rate moder increas
convict pt may i-day led ceo
david cordani showcas strategi innov vision
financi outlook integr ci esrx despit weak
guidanc ep guid reiter
encourag long-term guidanc outlook revenu
growth medic cost trend target ep growth
capit lite busi model attract rang
 next year offer return debt capit
acceler growth medicar advantag new rang
commenc meaning departur histor
import proof point deal success nonetheless benefit
market regulatori landscap undergo transform chang
tangibl posit catalyst requir view stock
work nt administr cost synergi across ci esrx
acceler market expect slower materi
like limit posit ep revis growth like
accret ep least month maintain estim
guidanc re-affirmed ep target
month pt contempl price-to-earnings
averag ep estim stock trade
attract price-to-earnings today report well polici
catalyst drug price reform elect debat rhetor
import catalyst next six nine month
posit
i-day vision integr ci esrx across
specialti rx accredo evicor pharmaci enabl physician
collabor data analyt compel acceler
approv gener biosimilar catalyz polici chang could
becom tailwind margin health servic segment
competitor op enjoy proven success meaning
growth market share gain even optum saw growth
ci manag team led ceo david cordani proven
track record success growth margin expans
analyst franchis cover ci year highest
respect leadership team transform custom focu
drive medic cost structur advantag therebi growth market
average
net debt total capit
price-to-earnings lt ep growth
share outstand mil share outstand
estimate lt ep growth compound-annual-growth-rate
year price history/av daili volume mil ci
compani inform svb leerink llc research
revenu ep forma ci-esrx ex-antm
revenu billion ep exclud item non-gaap ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
ci esrx busi model capit lite despit
leverag compani outlook gener
acceler pois drive acceler
de-lever debt cap
financi side long-term outlook offer i-day
compel target industri lead medic trend mirror
cpi revenu growth ep ci-esrx
model capit lite solid gener target debt cap
expect
howev challeng remain make show-m stori
market landscap meaning transform sinc optum
enjoy meteor success integr whole person model
enabl data analyt ci achiev industri lead
growth especi employ market larg vertic deal
ci esrx op aet acceler in-sourc pbm
op op /wcg op govern market
meaning intensifi competit across market segment nfp
blue seem acceler partnership
medicaid collabor compet directli
ci aet
medicar advantag growth guid rang
membership growth like import proof point
deal success given integr specialti rx asset accredo
specialti benefit platform evicor ci medic behavior
physic collabor arrang underpin
improv medic cost structur drive share gain
manag still see growth employ select market
platform like continu even amid heighten competit intens
slow growth observ compar histor
regulatori reform anoth wrinkl contend amid deal
integr see investor fear regulatori chang includ
rebat spread price overblown add anoth wrinkl
margin preserv pbm busi massiv
ci mix track record success deal
integr great west home run though ma-
focus health spring deal experienc challeng
membership growth margin regulatori sanction
stock like found bottom view posit
catalyst need stock work nt even trade
attract valuat investor seek proof point guid growth
least low end guidanc re-acceler
commerci growth select/middl market back histor
focu margin preserv even adjust script
grow roughli includ in-sourc mm ci
import upcom catalyst allevi concern
weaker especi segment
offer confid strategi growth model amid chang
manag view weaker line expect
season cadenc pois drive solid earn achiev
guid rang though posit revis acceler
polici catalyst drug price reform medicare-
for-al also key multipl expans final part
rebat rule latest guidanc plan bid line
histor disposit rebat premium subsidi could offer closur
possibl bipartisan legisl drug price part design
generics/biosimilar may also materi near futur
reiter op rate moder increas convict pt may
i-day led ceo david cordani showcas strategi innov vision financi
outlook integr ci esrx
despit weak guidanc ep guid reiter
encourag long-term guidanc outlook revenu growth medic cost trend
target ep growth capit lite busi model attract rang
 next year offer return debt capit acceler
growth medicar advantag new rang commenc meaning
departur histor import proof point deal success
nonetheless benefit market regulatori landscap undergo transform
chang tangibl posit catalyst requir view stock work nt
administr cost synergi across ci esrx acceler market
expect slower materi like limit posit ep revis growth
like accret ep least month
maintain estim guidanc re-affirmed ep target
month pt contempl price-to-earnings averag
ep estim stock trade attract price-to-earnings today report
well polici catalyst drug price reform elect debat rhetor
import catalyst next six nine month
ci host first investor day post esrx deal may nyc addit
present ceo david cordani tim wentworth cfo eric palmer multipl session
led season leader differ busi segment includ matt mander
brian evanko mike triplett jason sadler dr steve miller break-out session across whole
member health data analyt specialti rx showcas ci esrx
innov custom
i-day vision integr ci esrx across specialti rx accredo evicor
pharmaci enabl physician collabor data analyt compel
acceler approv gener biosimilar catalyz polici chang could becom
tailwind margin health servic segment competitor enjoy
proven success meaning growth market share gain even optum saw
growth margin expans
i-day laid admir goal reduc medic cost trend cpi
reduct trend current level would make trend
far best class competitor hover around would driven integr
express script includ power accredo specialti pharmaci evicor medic
manag solut focu whole-person health includ medic cost
result behavior lifestyl choic innov provid partner
collabor account care relationship alreadi run ci leverag vast data
asset deriv million custom relationship advanc analyt wrap around
key driver enabl acceler reduct medic cost trend
cigna laid goal reduc medic trend cpi
develop integr busi model
us well-articul medic cost trend goal make sens integr offer
enabl data analyt clear want seen simpli
insur compani pbm rather health servic compani attack
press issu healthcar multipl front accord manag closer
integr express script enabl better manag prescript drug trend
particularli specialti largest contributor growth healthcar cost
leverag power accredo evicor benefit integr medic
busi critic control healthcar spend accredo express script specialti
pharmaci broadest access exclus limit distribut drug
industri also capabl manag usag adher enabl pharmaceut
compani enter value-bas care arrang evicor express script medic
benefit manag solut engag provid cover live offer
protocol nine clinic area accredo evicor better abl manag medic
pharmaci cost togeth
focu whole person heath
integr solut set believ best posit focu whole-
person health sick care laid strategi focu whole person
mind bodi rather treat individu sick care event reactiv accord
medic cost result condit behavior lifestyl choic
engag member treat physic ailment mission critic reduc
spend report custom integr medic behavior pharmaci solut
save per employe per year pepi
ci focus whole person health across behavioral/lif style chang
intervent medic intervent
value-bas care program third leg stool reduc medic cost trend today
collabor account care relationship believ gener
provid align earn provid trust enabl compani design right share
reward program fuel innov report medicar payment
value-bas arrang account program physician meet
exceed qualiti benchmark futur plan appli value-bas
arrang specialist impact outcom burdensom health
data analyt enabl acceler medic trend reduct
ci intend leverag vast data asset enabl acceler medic cost reduct
see connect tissu patient provid data
analyt core drive connect appli advanc analyt vast trove
pharmaci behavior medic data iter best way direct care drive save
break-out session live demo innov center team member
reifi use data analyt moder medic trend
data digit tool brighter abl effici guid member highest
perform pcp base cost outcom brighter allow member plug person
inform return highest qualiti pcp area member get cost estim
read review eventu schedul appoint also abil access telehealth
via brighter tool use american mdlive network
also gave attende hand demo health connect view seem
similar optum ihr health connect develop express script provid
holist view patient gener person clinic care plan outcom
tool express script guarante member adher clinic outcom current
chronic condit tool track alert care coordin provid gap care
real time basi
also impress cigna one guid tool view critic direct
patient best site care avail member one guid provid high-touch
concierge-lik servic help member determin next best action guid
effici take step report patient use one guid higher
engag chronic condit coach higher use higher-perform provid
increas prevent care usag led reduc medic cost
use digit tool vs dont
ci manag team led ceo david cordani proven track record success
growth margin expans analyst franchis cover ci year
highest respect leadership team transform custom focu drive
medic cost structur advantag therebi growth market share gain
ci esrx busi model capit lite despit leverag gener
 acceler short-term blip
pois drive acceler de-lever debt cap
compani plan meaning expand capac capit deploy prioriti creat
bigger opportun deeper reinvest busi opportun return
capit back sharehold
ci expect cash flow oper cover debt repay
 share repurchas ci expect cash flow oper
lower compar lower contribut transit client higher
chang nwc ci plan alloc debt repay
 growth capit defin capit avail fund surplu activ return
sharehold gener avail discretionari deploy ci expect gener
 cash flow oper avail growth capit
initi ci pois drive acceler de-lever debt cap
ci oper expect increas
financi side long-term outlook offer day compel target
industri lead medic trend mirror cpi revenu growth
ci manag nt prioriti de-lever reinvest back busi near-term top capit deploy prioriti acceler de-lever track return debt-to-cap ratio end on-going basi capit prioriti remain first reinvest back busi continu growth second deploy capit strateg third return addit capit sharehold eric palmerchief offic corp corpor
ep ci-esrx model capit lite solid gener target debt cap
expect
ci significantli reduc portion busi driven highli regul capital-
intens insur product allow compani convert higher portion earn
deploy capit ci work provid retail help reduc cost becom
capital-effici
jason sadler offer updat busi remain differenti
high barrier entri growth tailwind driven emerg middl class particularli
asia korea china jv import market still offer addit
room growth increas penetr smaller book busi au/nz eu
also driver growth
ci benefit global trend growth middl class continu
acceler emerg develop market forecast two-third world
middl class live asia global age popul peopl age
 steep rise chronic diseas access afford healthcar
ci growth expect china complement histor revenu compound-annual-growth-rate
market landscap meaning transform sinc optum enjoy meteor
success integr whole person model enabl data analyt ci
achiev industri lead growth especi employ market larg vertic
deal ci esrx aet acceler in-sourc pbm
cnc/wcg govern market meaning intensifi competit across market
segment nfp blue seem acceler partnership medicaid
collabor compet directli ci aet
market competit intensifi creation new vertic integr mco
transform landscap expect retain express script client
grow pharmaci script expect build
deeper client relationship deliv greater innov express script
leverag accredo specialti pharmaci accord continu
express script best class pharmaci trend better closest
competitor continu valu creation
cigna expect retain client grow script
cigna believ express script best class pharmaci trend lead client retent
note optumrx last releas drug trend report
medicar advantag growth guid rang membership growth like
import proof point deal success given integr specialti rx asset
accredo specialti benefit platform evicor ci medic behavior
physician collabor arrang underpin improv medic cost structur
drive share gain manag still see growth employ select
market platform like continu even amid heighten competit intens
slow growth observ compar histor
ci target enrol growth long-term basi
regulatori reform anoth wrinkl contend amid deal integr
see investor fear regulatori chang includ rebat spread price overblown
add anoth wrinkl margin preserv pbm busi massiv
though two-year demonstr shift rebat po rule appear
place ice appetit bipartisan legisl drug price reform
regard pbm transpar part cap pocket spend heighten possibl
legisl market base chang continu commerci employ sponsor
market ci manag see rebat chang spread price govern take
choic client believ either regul repres risk growth
margin trajectori busi
hh rebat rule seek elimin rebat medicar part
eas transit two-year demonstr pilot
april issu guidanc backstop part plan margin chang drug
manufactur rebat two-year demonstr pilot memo state
govern would bear differ target actual incur cost
beyond first bp plan particip
rebat rule may put hold administr mull potenti drug
industri confer may link former fda commission scott gottlieb note part rebat rule
big price tag associ administr congress may want delay implement
use save pay cap out-of-pocket oop cost drug medicar part potenti drug
reform bi-partisan support includ legisl increas access gener biosimilar
increas transpar expand report requir pharmaci benefit manag pbm
health plan
ci manag prepar dynam environ speak flexibl busi modeland context hh rebat propos therefor repres risk growth trajectori howev help client reli rebat help off-set cost benefit provid also frankli propos lower cost beneficiari requir drug maker actual reduc price timothi wentworthpresid express script serviceslastli need keep busi posit dynam marketplac flexibl option strateg platform capit free cash flow sought deliber well within portfolio kind portfolio manag philosoph point think realli relev comment made specif regul one regul sit say transcend busi cours next year two three year render abil chang peopl live better deliv afford client custom less valu go forward long continu innov deliv total valu david michael cordanipresid ceo director corp corpor
ci mix track record success deal integr great west
home run though medicar advantag spring deal experienc
challeng membership growth margin regulatori sanction
manag reiter signific progress made combin two
organ believ combin compani remain track substanti complet
integr end next year
stock like found bottom posit catalyst need stock work
nt even trade attract price-to-earnings averag ep
investor seek proof point guid growth least low end
guidanc re-acceler commerci growth select/middl market back
histor focu margin preserv even adjust script grow
roughli includ in-sourc mm ci script
manag affirm integr progress wellfin coupl minut combin rapidli approach midpoint progress well combin organ first foremost deliv commit client custom patient marketplac deliv strong first quarter line expect demonstr strength underli platform well leadership resili colleagu colleagu around world stay focus market commit secondli make good progress rel integr prioriti track substanti complet integr end next year third result acceler pursuit addit client segment geograph expans opportun contribut growth profil beyond exampl alreadi includ expand offer health plan client well geograph expans opportun hear colleagu today david michael cordanipresid ceo director corp corpor
ci trade ep multipl receiv diversifi mco
import upcom catalyst allevi concern weaker especi
segment offer confid strategi growth model
amid chang manag view weaker line expect season
cadenc pois drive solid earn achiev guid rang though posit
revis acceler administr synergi captur beyond mm appear unlik
tepid view
ci health servic segment margin compress
ci earningsreport estimatesstreetaccount consensusreport sequentialreport yoytot net pre tax incom loss group disabl incom loss oper per disabl n/acorpor corpor
howev manag expect earn catalyst
market growthselect market in-lin manag expect although set back-end load yearsur start erick actual section go give littl bit addit color relat sort expect perform bottom line first quarter busi perform well perform expect absolut track expect term full year growth may know busi histor somewhat back-end load look percentag earn come quarter-to-quart year differ term broadly-defin pattern would expect see saw great retent great claim growth new claim take time make profit obvious implement sell solut solv problem tim wentworthpresid express script cigna servic corpor
polici catalyst drug price reform medicare-for-al also key
multipl expans final part rebat rule latest guidanc
plan bid line histor disposit rebat premium subsidi could offer
closur possibl bipartisan legisl drug price part design generics/biosimilar
may also materi near futur
cap oop part spend increas access gener biosimilar increas transpar
administr goal
primari valuat methodolog base absolut price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform dcf valuat
leverag forward forecast wacc termin growth rate inform
potenti multipl expans along sector compani specif catalyst expect
greater potenti multipl expans dcf valuat point significantli upsid
peer current trade level free cash flow yield ratio also inform
potenti multipl expans except low ratio and/or high free cash flow yield
point potenti greater multipl expans
price target base price-to-earnings averag ep
non-profit bcb plan insur price irrat commerci market
medic cost trend come higher anticip potenti econom downturn
provid re-up intens servic deliveri cobra acceler uptak
member util care advanc layoff pandem
employ exit rapidli sponsorship health benefit combat medic
cost inflat catalyz econom downturn
risk declin invest yield invest impair
state-bas actuari rate review limit sound price underwrit caus
longer term state-bas insur exchang advers select reduc
sustain earn power employ dump employe health insur
exchang signific margin compress potenti downsid membership
top line also present long-term risk
polit shock lead singl payer
compani specif risk signific declin equiti market could result increas
fund compani pension oblig polit legal oper regulatori
econom risk foreign oper
integr regulatori risk across merg ci esrx
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level free cash flow yield ratio also inform
potenti multipl expans except low ratio and/or high free cash flow yield
point potenti greater multipl expans
pt contempl price-to-earnings averag ep
risk invest thesi valuat
legisl regulatori polici chang could either dis-intermedi
insur us benefit marketplac place unforeseen top-lin margin
headwind commerci medicar advantag medicaid dual elig book
not-for-profit health insur price irrat commerci health benefit
acceler employ exit sponsorship health benefit us
marketplac post implement afford act
advers select public exchang protect adequ given delay
true-up govern payment
acquisit asset without attract return capit investor
organiz and/or oper risk drive execut mis-step downsid risk
earn
pt contempl price-to-earnings averag ep
risk valuat includ
start-up cost underwrit issu associ new busi on-board
particularli challeng new popul dual elig
annual off-cycl rate chang state medicaid program
uncertainti associ competit bid process state
legisl regulatori judici polici chang medicaid entitl program
state feder suprem court level also risk consid
pt contempl price-to-earnings averag ep
underwrit risk aet asset trade peak margin commerci fulli insur
though medacorp commerci broker price survey give us confid price
environ remain appropri hard offer flat even potenti modestli
expand underwrit margin risk potenti futur margin compress aet health
insur even meaning given associ neg impact
debt ebitda load compani need focus debt pay next
month departur shawn guertin aet cfo slate becom cfo
make us less confid price postur health insur book commenc
new bulk compet share gain commerci medicar
macroeconom risk risk macroeconom downturn higher
defens pbm sub sector given cyclic correl retail front store sale
employ data
regulatori risk convinc pbm add valu earn
low probabl threat potenti drug manufactur rebat elimin off-set new
busi model includ administr fee and/or perform guarante expos
pbm retail pharmaci busi compar player
pbm risk
execut integr risk face greater risk well given integr
pbm broader organ also transform agenda around build
retail front model amid risk leverag balanc sheet
e-commerce/amzn greater exposur eros sale on-line channel
well given exposur retail front store retail pharmaci e-commerc though
larg price retail multipl expect less like pursu agenda
becom pbm given associ integr clinic evid base treatment guidelin
integr provid network domin captiv pbm model mega deal
remain posit reiter op rate month pt
contempl price-to-earnings averag ep
risk invest thesi valuat legisl regulatori
polici chang could either dis-intermedi health insur us benefit
marketplac place unforeseen top-lin margin headwind commerci medicar
advantag medicaid dual elig book busi not-for-profit health insur
price irrat commerci health benefit marketplac acceler employ exit
sponsorship health benefit us marketplac post implement
afford act advers select public exchang protect adequ
given delay true-up govern payment acquisit asset
without attract return capit investor organiz and/or oper risk
lead execut mis-step downsid risk earn acceler medic cost trend
util improv economi servic arena yet yield adequ
return capit
sotp valuat point per share expect premium toward much
potenti takeout price per share see like buyer light
synergi medicaid complet pbm across ingeniorx optum rx
optum rx seek specialti rx expect look region player shore
medicaid pois well build third-parti servic platform best
place well pay cash also like interest given medicaid focu strategi
bring pbm in-hous would like pay asset equiti rather cash
delev fide transact financi buyer also like suitabl strateg
buyer identifi
start-up cost underwrit issu associ new busi on-board
particularli challeng new popul dual elig
annual off-cycl rate chang state medicaid program
uncertainti associ competit bid process state
legisl regulatori judici polici chang medicaid
scale issu result loss specialti rx pharmaci contract
acquisit offer adequ return capit
upsid takeout substanti premium key risk
carve-out behavior health servic current state contract
pt contempl multipl averag
risk highlight first spike util on-board new state contract
dual elig integr second state-bas insur exchang result advers
select reduc sustain earn power third state-bas contract rate increas
suffici cover medic trend off-set industri fee medicaid premium fourth risk re-
procur exist contract could creat substanti downsid risk volatil fifth
legisl judici risk manag medicaid entitl extrem case singl
payer model also possibl downsid
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level
free cash flow yield ratio also inform potenti multipl expans
except low ratio and/or high free cash flow yield point potenti greater
rate outperform price target contempl price-to-earnings
averag cash ep
non-profit bcb plan insur price irrat commerci market
medic cost trend come higher anticip potenti double-dip recess
provid re-up intens servic deliveri cobra acceler uptak member util
care advanc lay-off pandem
employ exit rapidli sponsorship health benefit combat medic cost
inflat catalyz double-dip recess
risk declin invest yield invest impair
state-bas actuari rate review limit sound price underwrit caus substanti
long-term state base health insur exchang advers select reduc
sustain earn power employ dump employe health insur
exchang signific margin compress also potenti downsid membership
risk relat collect industri fee medicar medicaid premium
polit shock lead singl payer
compani specif risk downsid risk price target includ acquisit asset
arena yield adequ return capit
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level
free yield ratio also inform potenti multipl expans
except low ratio and/or high free yield point potenti greater
base rate wcg outperform pt contempl price-to-earnings
averag ep
downsid risk price target includ execut new state contract dual elig
award rate increas suffici cover medic trend state clawback tax off-set tax
reform tailwind potenti dial medicaid expans ky upsid risk price
target includ take-out larger player
cigna inc ci incom mail order pharmaci invest invest gain revenu expenseshealth care medic claim benefit mail order pharmaci cost good acquisit oper expens exclud special deal synergi benefit continu oper incom tax net growth yoyrevenu growth metricstot adj gdr gener dispens ep corpor
health enrol access/oth guarante guarante legaci servic great west medic membership medic membership gw corpor
